Projected Earnings Date: 2025-07-31    (Delayed quote data   2025-05-09)
Last
 20.02
Change
 ⇓ -0.42   (-2.05%)
Volume
  1,245,258
Open
 20.56
High
 20.96
Low
 19.96
8EMA (Daily)
 20.07
40EMA (Daily)
 18.66
50EMA (Daily)
 18.67
STO (Daily)
 77.576
MACD Hist (Daily)
 0.479
8EMA (Weekly)
 18.704
40EMA (Weekly)
 16.94
50EMA (Weekly)
 16.33
STO (Weekly)
 39.370
MACD Hist (Weekly)
 -0.351
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com